سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

transmedic pte ltd - ioversol - injection, solution - 741 mg/ml - ioversol 741 mg/ml

سنغافورة - الإنجليزية - HSA (Health Sciences Authority)

transmedic pte ltd - ioversol - injection - 741 mg/ml - ioversol 741 mg/ml

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - pimobendan - oral bolus, chewable - pimobendan pyridazinone active 2.5 mg/tb - cardiovascular system - dog | bitch | castrate | puppy - congestive heart failure | dilated cardiomyopathy | mitral and/or tricuspid regur | valvular insufficiency

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - pimobendan (unii: 34ap3bbp9t) (pimobendan - unii:34ap3bbp9t) - pimobendan 1.25 mg - vetmedin (pimobendan) is indicated for the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (mmvd) or dilated cardiomyopathy (dcm). vetmedin is indicated for use with concurrent therapy for congestive heart failure (e.g.,furosemide, etc.) as appropriate on a case-by-case basis. vetmedin should not be given in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. user safety warnings: not for use in humans. keep this and all medications out of reach of children. consult a physician in case of accidental ingestion by humans. animal safety warnings: keep vetmedin in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose. only for use in dogs with clinical evidence of heart failure. at 3 and 5 times the recommended dosage, administered over a 6-month

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - pimobendan - oral bolus, chewable - pimobendan pyridazinone active 5.0 mg/tb - cardiovascular system

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - pimobendan - oral bolus, chewable - pimobendan pyridazinone active 1.25 mg/tb - cardiovascular system

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - pimobendan - oral bolus, chewable - pimobendan pyridazinone active 2.5 mg/tb - cardiovascular system

أستراليا - الإنجليزية - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - pimobendan - oral bolus, chewable - pimobendan pyridazinone active 10.0 mg/tb - cardiovascular system

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - pimobendan (unii: 34ap3bbp9t) (pimobendan - unii:34ap3bbp9t) - for the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular insufficiency (mitral and/or tricuspid valve regurgitation). (see also section “dosage, routes and method of administration”). for the treatment of dilated cardiomyopathy in the preclinical stage (asymptomatic with an increase in left ventricular end-systolic and end-diastolic diameter) in doberman pinschers following echocardiographic diagnosis of cardiac disease (see section “special warnings” and “precautions for use in animals”). for the treatment of dogs with myxomatous mitral valve disease (mmvd) in the preclinical stage (asymptomatic with a systolic mitral murmur and evidence of increased heart size) to delay the onset of clinical symptoms of heart failure (see section “special warnings” and “special precautions for use in animals”). do not use pimobendan in hypertrophic cardiomyopathies or in diseases in which an improvement in cardiac output cannot be achieved for functional or anatomical re

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - pimobendan (unii: 34ap3bbp9t) (pimobendan - unii:34ap3bbp9t) - vetmedin-ca1 (pimobendan) is indicated for the delay of onset of congestive heart failure in dogs with stage b2 preclinical myxomatous mitral valve disease (2019 acvim consensus statement1 ). stage b2 preclinical myxomatous mitral valve disease (mmvd) refers to dogs with asymptomatic mmvd that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly. do not administer vetmedin-ca1 in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons. do not administer vetmedin-ca1 to dogs with stage a or b1 preclinical mmvd (2019 acvim consensus statement) due to the risk of cardiac pathology associated with exaggerated hemodynamic responses to vetmedin-ca1.